Foundayo (Orforglipron) Dosing Schedule: Week-by-Week Titration
Full Foundayo titration schedule
| Window | Dose |
|---|---|
| Weeks 1-4 | 0.8 mg |
| Weeks 5-8 | 2.5 mg |
| Weeks 9-12 | 5.5 mg |
| Weeks 13-16 | 9 mg |
| Weeks 17-20 | 14.5 mg |
| Weeks 21+ | 17.2 mg |
Schedule based on the FDA-approved Foundayo prescribing label and ATTAIN-1 trial protocol. Your prescriber may adjust pacing based on tolerability. Some patients pause at a given dose for 8-12 weeks instead of 4; others may not titrate above 5.5 or 9 mg if weight-loss goals are met.
Weeks 1-4
0.8 mgStarter dose. GI tolerability check.
What to expect: Mild nausea (resolves within 1-2 weeks for most patients), slight appetite suppression, possible mild fatigue. Weight loss in this window is typically 2-5 lb and is mostly water + early appetite reduction, not yet steady-state.
Watch for: Persistent vomiting >24 hours, signs of dehydration (dizziness, dark urine), severe abdominal pain, or inability to tolerate any food. These warrant a prescriber call before continuing to week 5.
Weeks 5-8
2.5 mgFirst efficacy-relevant dose. Most patients see weight loss accelerate.
What to expect: Stronger appetite suppression. Nausea may return for 1-2 weeks after the dose increase, then settle. Constipation and mild fatigue are common in this window. Weight loss typically picks up to ~1-2 lb/week.
Watch for: Severe constipation (no bowel movement for 4+ days), abdominal swelling, persistent loss of appetite to the point of skipping >2 meals/day, or signs of dehydration. Increase water and fiber intake proactively.
Weeks 9-12
5.5 mgMid-range maintenance dose. Many patients stop here if weight loss is on track.
What to expect: Sustained appetite suppression. GI side effects typically lighter than the 2.5 mg transition because tolerance builds. Weight loss continues at 1-2 lb/week for most patients; some plateau earlier.
Watch for: Significant lean-muscle loss (consult prescriber if you notice strength dropping or fatigue worsening despite stable diet). Add resistance training and protein intake (~1 g/kg body weight/day) to preserve muscle.
Weeks 13-16
9 mgHigher-efficacy dose. Most weight-loss patients land here for steady-state maintenance.
What to expect: Weight loss continues at 0.5-1.5 lb/week. Appetite suppression may feel "automatic" by this point. Side effects usually mild and tolerable.
Watch for: New-onset gallbladder symptoms (right upper abdominal pain, especially after fatty meals). Rapid weight loss raises gallstone risk; ~1-2% of GLP-1 patients in trials had gallbladder events.
Weeks 17-20
14.5 mgHigh dose. Used when 9 mg is well-tolerated and the patient has not yet reached goal weight.
What to expect: Maximum or near-maximum efficacy for most patients. Weight loss continues but may slow as you approach your new metabolic set point. Some patients report intensified taste changes (food preference shifts).
Watch for: Pancreatitis warning signs (severe abdominal pain radiating to the back, persistent vomiting). Rare but documented in GLP-1 receptor agonist class. Discontinue and seek immediate care if these occur.
Weeks 21+
17.2 mgMaximum approved dose. Reserved for patients who tolerate 14.5 mg and need additional efficacy.
What to expect: Marginal additional weight loss vs 14.5 mg. Side effect profile similar. Most prescribers do not push to 17.2 mg unless the patient specifically needs it and tolerates lower doses without issue.
Watch for: Diminishing returns: if you have plateaued at 14.5 mg for 8+ weeks, increasing to 17.2 mg often produces only 1-2 more lb of loss. Consider this carefully against the cost (highest dose tier on LillyDirect, $299/mo in-window or $349/mo out-of-window).
How dose maps to LillyDirect pricing
LillyDirect prices Foundayo by dose tier. Within the 45-day refill window:
- 0.8 mg: $149/month
- 2.5 mg: $199/month
- 5.5 / 9 / 14.5 / 17.2 mg: $299/month
Outside the 45-day refill window, the highest doses (14.5 and 17.2 mg) move to $349/month standard pricing. Set a calendar reminder for day 30 of your supply to keep within the window. Full pricing breakdown including the Foundayo Savings Card paths.
Frequently asked questions
When should I take Foundayo each day?
Any time of day, with or without food. Foundayo is a non-peptide small molecule (orforglipron), unlike the peptide GLP-1s (semaglutide, tirzepatide) that require subcutaneous injection or strict fasting (oral Wegovy 25 mg). The convenience advantage is the headline reason patients consider Foundayo over oral Wegovy. Many prescribers suggest taking it at the same time each day for consistency, but the FDA label does not require it. Some patients prefer evening dosing so they "sleep through" the peak nausea period during titration.
What if I miss a dose?
If you remember within 12 hours of your usual time, take it as soon as possible. If more than 12 hours has passed, skip the missed dose and resume your normal schedule the next day. Do NOT double up. Skipping a single dose typically has minimal impact on overall weight loss because Foundayo has a half-life that allows for steady-state drug levels with daily dosing.
What if I miss multiple doses in a row?
For gaps of 1-5 days, simply resume your current dose the next day. For gaps of 5-14 days, message your prescriber - some will recommend stepping back to the previous dose for 1-2 weeks before resuming your higher dose to avoid GI side-effect rebound. For gaps over 14 days, expect to restart titration from a lower dose (typically 2.5 mg or even 0.8 mg) because your body has reset to baseline GLP-1 receptor sensitivity.
Can I stay on a lower dose forever?
Yes, if it is working. There is no clinical requirement to escalate beyond the dose where you achieve your weight-loss goal. Many patients stop at 5.5 mg or 9 mg permanently because those doses deliver enough weight loss at a manageable side-effect profile. Higher doses add efficacy but also add cost (the LillyDirect dose tiers jump from $149 at 0.8 mg to $299 at 5.5 mg and up). Your prescriber will set the target dose with you based on weight goal, tolerability, and cost considerations.
Why does each dose increase trigger nausea again?
Foundayo activates GLP-1 receptors in your gut and brain. Each dose increase produces a stronger receptor activation signal than your body has adapted to, which triggers the same nausea and constipation cycle you saw at 0.8 mg. The good news: each titration nausea period typically lasts 1-2 weeks before your body adapts. The pattern is normal across all GLP-1 receptor agonists (Wegovy, Zepbound, Ozempic, Mounjaro all do this).
How do I manage GI side effects during titration?
Stay hydrated (sip water rather than gulping; aim for 80+ oz/day). Eat smaller, more frequent meals; avoid greasy, fried, or spicy foods during dose-increase weeks. Try ginger tea or peppermint for nausea. For constipation: increase fiber gradually (rapid fiber increases worsen constipation in GLP-1 patients), increase water, add a daily walk. Magnesium glycinate (200-400 mg at bedtime) is well-tolerated for chronic constipation in this context. For severe nausea, ask your prescriber about a 1-2 week pause before continuing to the next dose.
Can my prescriber skip doses if I tolerate the current one well?
Not really. Each dose step has clinical rationale: receptor adaptation takes ~4 weeks regardless of how well the previous dose felt. Skipping from 0.8 mg directly to 5.5 mg usually triggers severe nausea + vomiting + dehydration even in patients who handled 0.8 mg perfectly. Most prescribers follow the standard 4-weeks-per-dose protocol. The exception: patients switching from a similar-mechanism GLP-1 (Wegovy, oral Wegovy) may start at 2.5 mg Foundayo instead of 0.8 mg because GLP-1 receptor tolerance carries over partially.
How long until I see weight loss?
Most patients see ~3-5 lb loss in weeks 1-4 (largely water + appetite reduction). Steady fat loss begins around week 5-8 once you reach the 2.5 mg dose. At 12 weeks (the 5.5 mg dose), expect 8-15 lb of loss from your starting weight depending on starting BMI and adherence. Full trial-level efficacy (14.7% mean weight loss in ATTAIN-1) lands around week 72, but most patients see the majority of their loss by month 6.
Do I take Foundayo forever?
GLP-1s are typically lifelong medications for weight loss. Trial data and real-world evidence show patients regain a substantial portion of lost weight within 12 months of stopping. If long-term treatment is not financially or logistically feasible, options include: (a) reducing to the lowest effective maintenance dose to minimize cost, (b) combining with structured lifestyle program for better post-discontinuation maintenance, or (c) transitioning to a less-expensive alternative if available. Discuss with your prescriber before stopping.
What happens if I become pregnant while on Foundayo?
Stop Foundayo immediately and contact your prescriber. GLP-1 receptor agonists (including Foundayo) are not recommended during pregnancy due to potential fetal harm based on animal studies. Lilly recommends stopping the drug at least 2 months before a planned pregnancy because of the long half-life. If you discover pregnancy while on Foundayo, your prescriber will likely have you stop and may refer you to maternal-fetal medicine. Most patients can safely restart after pregnancy and breastfeeding end.
Related guides
Track Foundayo (orforglipron) pricing and availability
Eli Lilly's daily oral pill Foundayo (orforglipron) was FDA-approved April 1, 2026 and starts at $149/mo via LillyDirect. We'll email you when pricing tiers change, insurance coverage expands, or new head-to-head data lands vs. Wegovy and Zepbound.